SODIUM IODIDE I 123
LOE ApproachingNDAORALCAPSULEPriority Review
Approved
Mar 1976
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Priority Review
SODIUM IODIDE I 123 by GE HealthCare is clinical pharmacology sodium iodide i-123 is readily absorbed from the upper gastrointestinal tract. First approved in 1976.
Drug data last refreshed 22h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Sodium Iodide I-123 is an oral radioiodine capsule used for thyroid imaging and functional assessment. The drug is readily absorbed from the gastrointestinal tract and selectively concentrated by the thyroid gland, allowing clinicians to visualize thyroid anatomy and detect abnormal tissue function. It works by being trapped and organically bound within thyroid tissue, providing diagnostic information in the absence of confounding factors like high iodine intake or interfering medications.
LOE Approaching
This diagnostic imaging agent faces approaching loss of exclusivity with low competitive pressure (30%), suggesting a stable but mature market with limited team expansion opportunities.
Mechanism of Action
CLINICAL PHARMACOLOGY Sodium iodide I-123 is readily absorbed from the upper gastrointestinal tract. Following absorption, the iodide is distributed primarily within the extracellular fluid of the body. It is trapped and organically bound by the thyroid and concentrated by the stomach, choroid…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on Sodium Iodide I-123 offers limited career growth given its mature, diagnostic-only profile and approaching loss of exclusivity. Opportunities exist primarily in specialized areas such as nuclear medicine medical affairs, regulatory compliance, and manufacturing optimization rather than high-visibility commercial roles.
Worked on SODIUM IODIDE I 123 at GE HealthCare? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.